Chinese artificial intelligence (AI) software developer Infervision completed a 300 million yuan ($47 million U.S.) series B+ round from existing investors Sequoia Capital China, Qiming Venture Partners, and Genesis Capital, according to a report from China Money Network.
New investors include Xianghe Capital, a venture capital firm funded by Hesong Tang, Baidu's former head of corporate development, and Advantech Capital, a private equity fund focusing on IT and medical industries.
Beijing-based Infervision applies deep-learning technology to assist in medical image diagnosis, particularly for lung cancer on CT exams. Its AI-CT technology is especially sensitive to semisolid and ground-glass nodules, according to the firm. Infervision's AI-DR targets cardiothoracic lesions and can reduce digital radiography (DR) analysis time from 10 minutes to five seconds, according to the firm.
Infervision has operations in Shanghai, Wuhan, Dalian, and Guangzhou, as well as offices in the U.S., Japan, and Germany.
